Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Position Raised by Dynamic Technology Lab Private Ltd

Dynamic Technology Lab Private Ltd lifted its position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 309.0% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 19,150 shares of the company’s stock after acquiring an additional 14,468 shares during the period. Dynamic Technology Lab Private Ltd’s holdings in Amphastar Pharmaceuticals were worth $711,000 as of its most recent filing with the SEC.

A number of other large investors have also modified their holdings of the company. Smartleaf Asset Management LLC grew its position in Amphastar Pharmaceuticals by 222.1% in the 4th quarter. Smartleaf Asset Management LLC now owns 715 shares of the company’s stock worth $26,000 after purchasing an additional 493 shares during the last quarter. Parkside Financial Bank & Trust grew its holdings in Amphastar Pharmaceuticals by 806.5% in the 4th quarter. Parkside Financial Bank & Trust now owns 979 shares of the company’s stock worth $36,000 after buying an additional 871 shares in the last quarter. Huntington National Bank increased its position in Amphastar Pharmaceuticals by 36.9% in the 4th quarter. Huntington National Bank now owns 1,340 shares of the company’s stock valued at $50,000 after acquiring an additional 361 shares during the period. TD Private Client Wealth LLC raised its stake in Amphastar Pharmaceuticals by 22.7% during the 4th quarter. TD Private Client Wealth LLC now owns 2,099 shares of the company’s stock valued at $78,000 after acquiring an additional 388 shares in the last quarter. Finally, KBC Group NV boosted its position in Amphastar Pharmaceuticals by 43.1% during the 4th quarter. KBC Group NV now owns 2,159 shares of the company’s stock worth $80,000 after acquiring an additional 650 shares during the period. Institutional investors and hedge funds own 65.09% of the company’s stock.

Amphastar Pharmaceuticals Trading Down 2.3 %

Amphastar Pharmaceuticals stock opened at $26.61 on Monday. Amphastar Pharmaceuticals, Inc. has a 12-month low of $25.73 and a 12-month high of $53.96. The company has a debt-to-equity ratio of 0.82, a current ratio of 3.43 and a quick ratio of 2.61. The stock has a market capitalization of $1.27 billion, a PE ratio of 8.87, a price-to-earnings-growth ratio of 2.19 and a beta of 0.79. The firm has a 50 day simple moving average of $30.24 and a 200-day simple moving average of $39.18.

Insiders Place Their Bets

In other news, CFO William J. Peters sold 4,231 shares of the business’s stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $27.54, for a total value of $116,521.74. Following the sale, the chief financial officer now owns 97,363 shares of the company’s stock, valued at approximately $2,681,377.02. The trade was a 4.16 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 27.10% of the stock is currently owned by insiders.

Analyst Ratings Changes

Separately, Piper Sandler lowered their price target on Amphastar Pharmaceuticals from $36.00 to $32.00 and set a “neutral” rating on the stock in a report on Friday, March 21st.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.